Theraclion S.A.
ALTHE.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$48.98M
Close$
$-0.62
194.9% downside
Current Fair Value
194.9% downsideOvervalued by 194.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $48.98 Million |
|---|---|
| Enterprise Value | $52.90 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.1 |
| Beta | 0.42 |
| Outstanding Shares | 73,144,000 |
Return
| Return on Equity | 3213.58% |
|---|---|
| Return on Assets | -85.87% |
| Return on Invested Capital | -125.89% |
Valuation & Multiples
| P/E Ratio | -6.47 |
|---|---|
| PEG | -16.1 |
| Price to Sales | - |
| Price to Book Ratio | -0.65 |
| Enterprise Value to Revenue | 17.5 |
| Enterprise Value to EBIT | -3.98 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -12.52 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 16, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Theraclion S.A.
36 employees
CEO: Martin Deterre Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include S...